Selective inhibitor of tumor necrosis factor α (TNF-α). Formerly used as sedative, hypnotic. Prepn: GB 768821 (1957 to Chemie Grünenthal). Teratogenicity studies: I. D. Fratta et al., Toxicol. Appl. Pharmacol. 7, 268 (1965). Review of proposed mechanisms of embryopathy: T. D. Stephens, Teratology 38, 229-239 (1988). HPLC determn in plasma: A. Delon et al., J. Liq. Chromatogr. 18, 297 (1995). Stereospecific determn and pharmacokinetics of enantiomers: T. Eriksson et al., Chirality 7, 44 (1995). Clinical trial in HIV wasting syndrome: G. Reyes-Terán et al., AIDS 10, 1501 (1996); in aphthous ulcers related to HIV infection: J. M. Jacobson et al., N. Engl. J. Med. 336, 1487 (1997). Review of chemistry, pharmacokinetics and clinical safety: V. Günzler, Drug Saf. 7, 116-134 (1992); of effect on TNF-α and clinical use in leprosy and tuberculosis: J. D. Klausner et al., Clin. Immunol. Immunopathol. 81, 219-223 (1996); of pharmacology, history and potential clinical uses: D. Stirling et al., J. Am. Pharm. Assoc. NS37, 307-313 (1997); of use in multiple myeloma: S. V. Rajkumar, Expert Rev. Anticancer Ther.1, 20-28 (2001); of pharmacology and toxicology: C. Meierhofer, C. J. Wiedermann, Curr. Opin. Drug Discov. Devel. 6, 92-99 (2003); of clinical experience: S. J. Matthews, C. McCoy, Clin. Ther. 25, 342-395 (2003).
Immunomodulator.
Sedative/Hypnotic; Piperidinediones; Immunomodulator